AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05176756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification and Social Support
Description: Participants will be entered into a points and levels-based game designed to help them meet their step count goals. At the start of each week, the participant will receive a set amount of points. Each day their step goal is not met, they lose points. If the participant meets a certain point value at the end of the week, they will either advance one level (of five total levels); if they do not, they will drop one level. Each participant will also select a family member or friend or the study coordinator to serve as a support partner. At the beginning of the intervention, the participant and support partner will identify at least 3 ways in which they can help the participant meet their step goals. This partner will receive a weekly email reminding them of these approaches and updating them on the participant's progress.
Study NCT05176756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Participants will receive a daily text message with their step count from the day prior.
Study NCT05873933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemptress Oil
Description: Full ingredient list of the test product: Rubus occidentalis (Black raspberry) seed oil\*, Carica papaya (Papaya) seed oil\*, Bixa orellana (Annatto) seed oil\*, Orbignya oleifera (Babassu) seed oil\*, Borago officinalis (Bourrache) seed oil\*, Daucus carota (Carrot) seed oil\*, Hibiscus sabdariffa (Hibiscus) seed oil\*, Aronia melanocarpa (Chokeberry) seed oil\*, Vaccinium macrocarpon (Cranberry) seed oil\*, Moringa oleifera (Moringa) seed oil\*\*, Persea americana (Avocado) oil\*, Ribes nigrum (Black currant) seed oil\*, Copaifera officinalis (Copaiba) resin\*, Canabis sativa (Hemp) seed oil\*, Moringa peregrina seed oil extract \& Caprylic/Capric Triglyceride\*\* (Moringa peregrina extract), Ascorbyl tetraisopalmitate (Vitamin C), Proprietary full-spectrum blend of Cannabis sativa (Hemp) extract, Silica (Algica), Ergocalciferol (Vitamin D2), Menaquinone (Vitamin K2), Tocopherol (Vitamin E)\* Organic Ingredient\* Wild Crafted/Regenerative\*\*
Study NCT00610337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethrin® (BA-210)
Description: Intraoperative epidural administration during spinal decompression surgery
Study NCT06208566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversational Agent Zenny
Description: The intervention group involves a newly developed conversational agent self-care program. This program consists of 40 separate modules based on empirically supported techniques. Modules include the following core sections: cognitive behavioral skills, interpersonal relationships, positive psychological growth, relaxation, goal setting, and emotional regulation skills. The modules focus on cognitive-behavioral skills for reducing emotional distress, improving behavioral activation and healthy behaviors, and problem-solving skills. The intervention was delivered via a decision-tree based conversational agent in WhatsApp messenger.
Study NCT04745403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA HBV/TCR T-cells
Description: Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW.
Study NCT06208566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based Wellness Resources
Description: The control group involved referral to a menu of freely-available evidence-based wellness resources linked from the study website, Your Healthiest Self: Wellness Toolkits, Doing What Matters in Times of Stress, and How Right Now. These website choices involved self-selection of relevant modules for improving mood, reducing stress and anxiety, addressing relationship problems, and other wellness topics. These programs required only access to the websites and could be completed in a self-help format by participants at their own pace.
Study NCT04708860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Nightly Fasting
Description: Restriction of consumption of calorie-containing food/drinks after 8pm
Study NCT04708860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Personalized moderate-intensity, aerobic exercise and strength training
Study NCT06089941 — intervention group
Intervention type: OTHER
Intervention: circulating tumoral DNA detection
Description: blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse
Study NCT00610337 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Spinal decompression surgery without administration of Cethrin® BA-210
Study NCT06358794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Machine learning-based predictive model
Description: The clinical features of participants were used to train, test and validate the machine learning models. Various evaluation metrics including area under the ROC (AUC), accuracy, etc. were used to evaluate the predictive performance of 8 machine learning models.
Study NCT06510400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMNICHROMA
Description: supra nano filled composite
Study NCT06510400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceram. x spectra
Description: nano hybrid composite resin
Study NCT06454149 — intervention group
Intervention type: OTHER
Intervention: MALT lymphoma
Description: New diagnosis with gastric MALT lymphoma
Study NCT04994093 — intervention group
Intervention type: OTHER
Intervention: Collection of blood (PBMC), biopsy (FFPE) and stool samples.
Description: Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).
Study NCT06632652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Provide 'Health Education' for acquisition of self-management skills, acquiring knowledge of both the disease and self-care. By making self-supported decisions, the patients are able to manage their diet, exercise and medication.~Patients will start implementing diabetes management right after the group education. Each patient will develop monthly goal settings (behavior change plan) related to their diabetes management, daily practice them, and record the results every day on the self-monitoring notebook. The nurses call each patient on the scheduled day, ask/evaluate his/her behavior changes and monitored data, then make step-up goals for the next month. In addition, based on his/her knowledge and practice level, the nurses provide education using the education booklet. Patients and the nurses repeat these activities during 6 months.
Study NCT04805515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine Corrective Messages
Description: Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.
Study NCT06294418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Field Cycling Imaging (FCI)
Description: FCI scan
Study NCT04731987 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Beverage consumption
Description: Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal.
Study NCT04731987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage consumption
Description: Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal.
Study NCT05307809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample collection
Description: Blood sample collection
Study NCT05307809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood sample collection
Study NCT05307809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin sample collection
Description: Skin sample collection
Study NCT06386861 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Attitudes Toward Genomics and Precision Medicine (English)
Description: completing the English version of the AGPM and validated health literacy and numeracy instruments
Study NCT06386861 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Attitudes Toward Genomics and Precision Medicine (Spanish)
Description: completing the Spanish version of the AGPM and validated health literacy and numeracy instruments
Study NCT05518708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3032950
Description: BI 3032950
Study NCT05518708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04816318 — intervention group
Intervention type: OTHER
Intervention: Social and public health measures against COVID-19
Description: 1. Viral spread (for both outcomes) 1.1. Total lockdown 1.2 Partial lockdown (geographical, step-wise/graduated response) 1.3 Curfew 1.4 School closure 1.5 Closure of shopping malls, gyms, churches, parks 1.6 Remote work 1.7 Restrictions to national/subnational mobility 1.8 Prohibition of mass gatherings~2. Health systems response (for COVID-19 deaths outcome) 2.1 Interventions to increase testing capacity 2.2 Interventions to increase the number of ICU/critical beds~3. Mitigation strategies (for both outcomes) 3.1 Direct social assistance (in-kind/cash) 3.2 Cash transfer 3.3 Withdrawal of pension funds
Study NCT04816318 — intervention group
Intervention type: OTHER
Intervention: Control
Description: The comparator is a counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred (see Statistical Analysis Plan for definitions)
Study NCT06133296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fixed treatment
Description: Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment
Study NCT06133296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear aligner treatment
Description: After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments
Study NCT03966131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue pressure recordings with the PRESLA prothesis for the Arm1 (patients wearing the complete denture for the first time)
Description: Tongue pressure recordings during speech production, wet and dry swallowing tasks planned in 3 sessions, when the complete denture is worn for the first time, after 3 weeks, then after 3 months in order to characterise the adaptation to this new prosthesis.
Study NCT03966131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue pressure recordings with the PRESLA prothesis for the Arm2 (patients used to wear the complete denture)
Description: These measures provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during speech production in patients used to their prosthesis. They also provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during swallowing) in these patients. The measurement is made at once when the new denture which replaces the old one is placed in the mouth.
Study NCT06026501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PE0116,PE0105
Description: 1. PE0116: 4-1BB Agonist Antibody Drug~2. PE0105: PD-1 Monoclonal Antibody Drug
Study NCT05097105 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: MRI sequences: TI. T2 and diffusion weighted
Study NCT06402292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OSTEOMYELITIS SURGICAL TREATMENT WITH LOCAL ANTIBIOTICS AND PEROSSAL
Description: 25 PATIENTS WITH FRI WILL BE SURGICALLY TREAT WITH DESBRIDMENT AND PEROSSAL WITH ANTIBIOTCS
Study NCT06505993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Communication
Description: Participants will experience a coordinated social marketing campaign including targeted messaging related to vaccine education, self-efficacy, and informative resources to receive the COVID-19 vaccine. The intervention messaging will be strategically layered and disseminated to this intervention arm predominately via Facebook by trusted and local communicators in the study counties.
Study NCT06505993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Communication + Structural
Description: This multi-level intervention will include the defined health messaging intervention components, as well as a combination of structural-level intervention strategies targeted to better facilitate access to community-based vaccination delivery. Health organizations will receive a toolkit, which will include community-specific resources and training modules such as: up to date evidence-based vaccination guidance that can be delivered to patients; strategies for navigating conversations with patients about vaccination; any applicable reimbursement, insurance, or qualifying enrollment information specific to the healthcare organization; identifying locations that facilitate access for the community members; provided advertising to promote the locations and timing of the vaccinations; and generating community-based branding for all vaccination delivery based on the trusted information sources identified.
Study NCT04281355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of axillary lymph node dissection
Description: Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B
Study NCT04281355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Omission of regional irradiation
Description: Regional irradiation will be omitted in the interventional arm of Randomisation A.
Study NCT06547515 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy
Study NCT04799691 — intervention group
Intervention type: PROCEDURE
Intervention: Invasive ventilation strategy
Description: Use of an invasive ventilatory support strategy
Study NCT04799691 — intervention group
Intervention type: PROCEDURE
Intervention: Non-invasive ventilation strategies
Description: Use of non-invasive ventilatory support strategies
Study NCT05314933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-Deoxyglucose
Description: Intranasal administration
Study NCT05314933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal administration
Study NCT04845139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab given intraventricularly
Study NCT05837104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium vitamin B6
Description: Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
Study NCT05837104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, three times daily for four weeks.
Study NCT06194500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3549492
Description: Administered as oral solution.
Study NCT06194500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3549492
Description: Administered orally.
Study NCT06194500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3549492
Description: Administered as IV infusion.
Study NCT05323071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose 24%
Description: According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, >37 weeks : 1 mL
Study NCT05323071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose 24%
Description: According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, >37 weeks : 1 mL
Study NCT05558462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Study NCT05962359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Implemented Communication Treatment
Description: The intervention will be taught by a qualified professional online and/or in-person for about 6 months. Parents will learn strategies to enhance their children's social communication and will receive coaching and feedback.
Study NCT04779489 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: personalized ultrafractionated stereotactic ablative radiotherapy
Description: next-generation stereotactic ablative radiotherapy to bladder and enlarged lymph nodes
Study NCT06373887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant-based Low carbohydrate diet
Description: In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
Study NCT06373887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant-based Low low fat diet
Description: In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
Study NCT04732949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNG001
Description: SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
Study NCT04732949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
Study NCT00771121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urea/lactic acid
Description: new emulsion type
Study NCT00771121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: only emulsion base
Study NCT04861428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IQOS
Description: IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).
Study NCT04861428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IQOS
Description: IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).
Study NCT04861428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking as Usual
Description: Cigarette smoking
Study NCT04861428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking as Usual
Description: Cigarette smoking
Study NCT06047496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period.
Study NCT05191953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound-guided ESPB
Description: Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit.
Study NCT05191953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound-guided ESPB and superficial PIPB
Description: Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit.
Study NCT05637684 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low intensity pulsed ultrasound
Description: mechanical sound waves
Study NCT05402150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: * instruction to create a list of individual positive activities.~* instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity.
Study NCT05402150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindulness and Gratitude
Description: * instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with these pleasant impressions of the situation they reflected upon~* instruction to do a gratitude exercise and name one or more things they are generally grateful for each day.
Study NCT05402150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of Behavioral Activation and Mindfulness and Gratitude
Description: This group will do a combination of the two intervention types.